| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg | |||
| Other Sizes |
| Targets |
PF-06761281 targets the sodium-coupled citrate transporter (NaCT or SLC13A5), which transports dicarboxylates and tricarboxylates into cells along with sodium ions. It has IC50 values of 0.51 µM against HEKNaCT, 13.2 µM against HEKNaDC1, and 14.1 µM against HEKNaDC3, demonstrating partial selectivity for NaCT. Inhibition of NaCT reduces hepatic and renal citrate uptake.
|
|---|---|
| ln Vitro |
In rat, mouse, and human Heps, PF-06761281 (compound 4a) reduces citrate absorption with IC50 values of 0.12, 0.21, and 0.74 µM [1].
In vitro, PF-06761281 (Compound 4a) inhibits citrate uptake with IC50 values of 0.12 µM in rat hepatocytes, 0.21 µM in mouse hepatocytes, and 0.74 µM in human hepatocytes. It shows IC50 values of 0.51 µM against HEKNaCT, 13.2 µM against HEKNaDC1, and 14.1 µM against HEKNaDC3. |
| ln Vivo |
In vivo, PF-06761281 is orally active and reduces hepatic and renal citrate uptake as well as plasma glucose concentrations. It is used for metabolic disorder research. The compound's oral bioavailability supports its utility for studying citrate transport and metabolic regulation in vivo.
|
| Enzyme Assay |
Specific cell-free enzyme/receptor binding assay protocols for PF-06761281 involve citrate uptake inhibition assays using cells expressing recombinant transporters. IC50 values are determined for HEKNaCT (0.51 µM), HEKNaDC1 (13.2 µM), and HEKNaDC3 (14.1 µM). Citrate uptake is measured using radiolabeled citrate or fluorescent citrate analogs.
|
| Cell Assay |
In vitro cell-based assays for PF-06761281 use HEK293 cells expressing recombinant NaCT, NaDC1, or NaDC3 transporters. Cells are treated with the compound, and citrate uptake is measured using radiolabeled or fluorescent citrate. IC50 values are determined from concentration-response curves. Hepatocyte assays in rat, mouse, and human cells assess citrate uptake inhibition.
|
| Animal Protocol |
In vivo animal studies for PF-06761281 have been conducted in rodent models to assess its effects on citrate uptake and glucose metabolism. The compound is orally administered, and its effects on hepatic and renal citrate uptake and plasma glucose concentrations are measured. These studies support its potential for treating metabolic disorders.
|
| ADME/Pharmacokinetics |
PF-06761281 has a molecular formula of C13H17NO6 and a molecular weight of 283.28 g/mol. It has a LogP of 0.97 and a density of 1.4±0.1 g/cm³. The compound is soluble in water at ≥50 mg/mL. Appearance: off-white to light yellow solid powder. Storage: powder at -20°C for 3 years or 4°C for 2 years; in solvent at -80°C for 6 months or -20°C for 1 month.
|
| Toxicity/Toxicokinetics |
Specific toxicological data for PF-06761281 are not detailed in the available literature. The compound is classified for research use only and is not intended for human therapeutic applications. As a citrate transport inhibitor, potential toxicities would relate to effects on cellular metabolism and citrate homeostasis, though formal toxicological profiles are not reported.
|
| References | |
| Additional Infomation |
PF-06761281 (CAS 1854061-19-0) is a potent, orally active, partially selective NaCT/SLC13A5 inhibitor with IC50 values of 0.51 µM (HEKNaCT), 13.2 µM (HEKNaDC1), and 14.1 µM (HEKNaDC3). It inhibits citrate uptake in hepatocytes (IC50: 0.12-0.74 µM) and reduces plasma glucose. The compound is used in metabolic disorder research. No clinical trial data are available.
|
| Molecular Formula |
C13H17NO6
|
|---|---|
| Molecular Weight |
283.277184247971
|
| Exact Mass |
283.105
|
| CAS # |
1854061-19-0
|
| PubChem CID |
127029348
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
469.7±45.0 °C at 760 mmHg
|
| Flash Point |
237.9±28.7 °C
|
| Vapour Pressure |
0.0±1.2 mmHg at 25°C
|
| Index of Refraction |
1.571
|
| LogP |
0.97
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
21
|
| Complexity |
377
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CC(C)(C)C1=CC=C(C=C1)CC[C@@](CC(=O)O)(C(=O)O)O
|
| InChi Key |
QNFWRHKLBLSSPB-MRXNPFEDSA-N
|
| InChi Code |
InChI=1S/C16H22O5/c1-15(2,3)12-6-4-11(5-7-12)8-9-16(21,14(19)20)10-13(17)18/h4-7,21H,8-10H2,1-3H3,(H,17,18)(H,19,20)/t16-/m1/s1
|
| Chemical Name |
(2R)-2-[2-(4-tert-butylphenyl)ethyl]-2-hydroxybutanedioic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ≥ 50 mg/mL (~176.50 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5301 mL | 17.6504 mL | 35.3008 mL | |
| 5 mM | 0.7060 mL | 3.5301 mL | 7.0602 mL | |
| 10 mM | 0.3530 mL | 1.7650 mL | 3.5301 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
